Canadian Stocks Reverse Winning Streak, Led by Galaxy Digital
This article was automatically generated by MarketWatch using technology from Automated Insights.
Stocks in Canada slipped Friday, as the S&P/TSX Composite Index declined 0.8%, to 22059.03. The blue-chip S&P/TSX 60 dropped 0.8%, to 1,315.72.
Among large companies, Galaxy Digital Holdings posted the largest decline, dropping 5.9%, followed by shares of Kelt Exploration, which dropped 5.5%. Shares of Hammond Power Solutions fell 4.9%.
Hut 8 was the biggest gainer during the session, surging 11%, and Bitfarms surged 9.3%. Ivanhoe Electric rounded out the top three movers on Friday, as shares surged 6.9%.
Stock indexes in the U.S. increased with the Nasdaq Composite Index adding 0.9%. Meanwhile, the S&P 500 Index gained 0.5%, and the Dow Jones Industrial Average added 0.2%.
On the currency front, the WSJ Dollar Index fell 0.2%, to 99.81. Locally, the dollar was equivalent to CAD0.73, down 0.2%.
In the bond markets, the yield on 10-year Canadian government bonds declined 10.76 basis points, to 3.496%, and 10-year U.S. Treasury yields fell 0.08 basis point, to 4.282%.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
July 05, 2024 16:51 ET (20:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks